Hay fever is an allergic disorder caused due to the hyper reaction of the immune cells to pollen grains and airborne substances. It is also called allergic rhinitis. The hyperactivity of the immune cells is due to the presence of high levels of IgE antibodies, which are responsible for release of histamine in the body leading to allergic reactions. Allergic rhinitis is classified into three types: seasonal, perennial, and occupational. Seasonal allergic rhinitis is caused by the hypersensitivity and allergic reaction to the airborne substances such as pollen from grass & weeds and mold spores. Perennial allergic rhinitis is caused by inhalation of dander, pet hair, and dust mites. Occupational allergic rhinitis is characterized by intermittent or persistent symptoms of allergic rhinitis due to work environment. Common symptoms of allergic rhinitis include sneezing, watery eyes, itchy throat, and blocked and runny nose. Serious symptoms include headache, facial pain due to blocked sinuses, and spreading itchiness to nose and ear through throat. Some patients may also experience irritability, tiredness, and insomnia.
Allergic rhinitis is the fifth most common disease in the U.S. According to the American College of Allergy, Asthma & Immunology (ACAAI), 30% of global population is affected by allergic rhinitis. In the U.S., around 30 million people aged around 18 years and above were diagnosed with allergic rhinitis in 2016, accounting for 8.2% of the adult population. Furthermore, around 9%, or 6.1 million, children were diagnosed with allergic rhinitis, most common being the seasonal rhinitis occurring more often in summer, spring, and fall. The cost for treatment of allergic rhinitis in the U.S. is estimated at US$ 3.4 Bn
Major drivers of the Hay Fever market include rising prevalence of the allergy and changing lifestyle leading to decreased immune resistance. However, patent expiration, generic drug competition, and increasing shift from prescription products to OTC products restrain the allergic rhinitis market.
Based on drug class or treatment type, the global Hay Fever market has been segmented into decongestants, antihistamines, corticosteroids, leukotriene receptor antagonists, and immunotherapy (allergy shots). Antihistamines hold the major share of 60% of the allergic rhinitis market, as these are the preferred treatment option by physicians. Moreover, wide range of antihistamines are available for treatment of intermittent symptoms.
In terms of disease type, the global Hay Fever market has been classified into seasonal, perennial, and occupational. The seasonal allergic rhinitis segment holds major share of the market as it is the most common form of allergic rhinitis and occurs in around 20% of the allergic rhinitis patients. Occupational allergic rhinitis is quite rare and can be avoided with the change of working environment.
Based on route of administration, the market has been segmented into oral, intranasal, and intravenous. Intranasal is the preferred route of administration for allergic rhinitis as it would provide immediate relief from intermittent symptoms. Technological advancement is anticipated to boost the intranasal segment.
In terms of distribution channel, the global Hay Fever market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies hold the major share of the Hay Fever market as antihistamines are mostly prescribed for allergic rhinitis which is an OTC product. However, the online pharmacies segment is anticipated to experience moderate growth driven by advancements in technology.
In terms of region, the global Hay Fever market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The U.S. accounted for over 40% share of the Hay Fever market. The trend is projected to continue during the forecast period. However, growth is expected to be sluggish due to market saturation and generic competition. The market in Latin America is anticipated to experience moderate growth due to rising incidence of allergic rhinitis and the expanding immunotherapy market in Mexico and Brazil.
Major players in the global Hay Fever market are Sanofi, UCB, GlaxoSmithKline plc, Merck & Co, Inc., Meda Pharmaceuticals, Johnson & Johnson, Teva Pharmaceuticals, Novartis AG, Kyowo Hako Kirin, and Stallergenes Greer plc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.